Drug major Pfizer Inc. (PFE) announced Monday positive topline results from the progression-free survival or PFS analysis of the ...

Pfizer (PFE) announced positive topline results from the progression-free survival – PFS – analysis of the Phase 3 BREAKWATER study of Braftovi ...

NEW YORK - Pfizer Inc. (NYSE: NYSE:PFE), a pharmaceutical giant with a market capitalization of $150 billion and annual revenue exceeding $59 billion, announced today that its Phase 3 BREAKWATER study ...

Pfizer Inc. today announced positive topline results from the progression-free survival (PFS) analysis of the Phase 3 BREAKWATER study of BRAFTOVI® (encorafenib) in combination with cetuximab ...

We recently published a list of the 10 Best Cancer Stocks to Buy According to Hedge Funds. In this article, we are going to ...

PLX READ THE FULL PLX RESEARCH REPORT Reasons To Own / A Compelling Idea for 2025 Protalix Biotherapeutics, Inc. (NYSE:PLX) ...

A jab given to patients to battle RSV through the NHS could potentially cause a disabling condition known as Guillain-Barré ...

Health experts are seeing signs of a much smaller wave of U.S. COVID-19 cases this winter than in previous years, which could ...

Day One Biopharma's OJEMDA FDA approval for pediatric glioma, but market concerns remain. Check out why I rate DAWN stock as ...

Pfizer Ltd. key Products/Revenue Segments include Pharmaceuticals, Sale of services, Scrap for the year ending 31-Mar-2024.For the quarter ended 30-09-2024, the company has reported a Standalone Total ...